Concepts for Analgosedation During Placement of Regional Anaesthesia Before Operations.
NCT ID: NCT04026074
Last Updated: 2019-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2019-07-26
2019-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this double blind randomized trial the investigators will be testing the application of drugs administered intravenously (fentanyl-bolus, remifentanil-infusion, clonidine-bolus) or transcutaneously (EMLA salve) or placebo (NaCl 0,9% i.v. and skin protection salve).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protracted Effect of Combined Nerve Blocks After Total Knee Arthroplasty
NCT02067078
Comparison Between Blocks or Not in Joint Arthroplasty
NCT06230081
Perioperative Analgesia After Knee Arthroplasty
NCT01225484
The Analgesic Effect of Combined Nerve Block and Systemic High Dose Glucocorticoid After Total Knee Arthroplasty.
NCT02374008
Effectiveness of Ultrasound Guided Adductor Canal Block on Chronic Pain in Knee Osteoarthritis
NCT02695654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fentanyl i.v. (intravenously)
Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
Fentanyl
Weight adapted drug application
Placebo salve
Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Remifentanil i.v.
Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
Remifentanil
Weight adapted drug application
Placebo salve
Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Clonidine i.v.
Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
Clonidine
Weight adapted drug application
Placebo salve
Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
EMLA salve
Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo
EMLA Cream
Salve application on the body part where the regional anaesthesia will be administered
Placebo iv
i.v. administration of 0,9% NaCl
Placebo
Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)
Placebo iv
i.v. administration of 0,9% NaCl
Placebo salve
Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fentanyl
Weight adapted drug application
Remifentanil
Weight adapted drug application
Clonidine
Weight adapted drug application
EMLA Cream
Salve application on the body part where the regional anaesthesia will be administered
Placebo iv
i.v. administration of 0,9% NaCl
Placebo salve
Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Intolerance against study medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregor A Schittek, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Graz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Hospital LKH Graz
Graz, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.